Abstract
1316MO BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have